Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.

Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC, Leibovich BC.

Eur Urol. 2014 Nov;66(5):929-35. doi: 10.1016/j.eururo.2013.12.017. Epub 2013 Dec 25.

2.

External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.

Zigeuner R, Hutterer G, Chromecki T, Imamovic A, Kampel-Kettner K, Rehak P, Langner C, Pummer K.

Eur Urol. 2010 Jan;57(1):102-9. doi: 10.1016/j.eururo.2008.11.033. Epub 2008 Nov 28.

PMID:
19062157
3.

Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.

Kaushik D, Kim SP, Childs MA, Lohse CM, Costello BA, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH.

Eur Urol. 2013 Oct;64(4):600-6. doi: 10.1016/j.eururo.2012.12.023. Epub 2012 Dec 25.

PMID:
23280319
4.

High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.

Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC.

Cancer. 2006 Jul 1;107(1):37-45.

5.

Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).

Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, Chromecki T, Burger M, Wieland WF, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Feciche B, Truss M, Gilfrich C, Pahernik S, Hohenfellner M, Zastrow S, Wirth MP, Novara G, Carini M, Minervini A, Simeone C, Antonelli A, Mirone V, Longo N, Simonato A, Carmignani G, Ficarra V; Members of the CORONA project and the SATURN project.

Eur Urol. 2013 Sep;64(3):472-7. doi: 10.1016/j.eururo.2012.06.030. Epub 2012 Jun 22.

PMID:
22748912
6.

CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.

An H, Xu L, Chang Y, Zhu Y, Yang Y, Chen L, Lin Z, Xu J.

Eur J Cancer. 2015 Sep;51(14):1953-61. doi: 10.1016/j.ejca.2015.06.125. Epub 2015 Jul 15.

PMID:
26188847
7.

Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.

Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS.

BJU Int. 2012 Oct;110(7):956-60. doi: 10.1111/j.1464-410X.2012.10937.x. Epub 2012 Feb 2.

8.

External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.

Fujii Y, Saito K, Iimura Y, Sakai Y, Koga F, Kawakami S, Kumagai J, Kihara K.

J Urol. 2008 Oct;180(4):1290-5; discussion 1295-6. doi: 10.1016/j.juro.2008.06.014. Epub 2008 Aug 15.

PMID:
18707704
9.

Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.

Pan D, Xu L, Liu H, Zhang W, Zhu Y, Xu J, Gu J.

Jpn J Clin Oncol. 2015 Feb;45(2):202-9. doi: 10.1093/jjco/hyu194. Epub 2014 Nov 23.

10.

Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.

Weight CJ, Kim SP, Lohse CM, Cheville JC, Thompson RH, Boorjian SA, Leibovich BC.

Eur Urol. 2011 Sep;60(3):458-64. doi: 10.1016/j.eururo.2011.04.022. Epub 2011 Apr 16.

PMID:
21514718
11.

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, Pickering L, Gore M, Larkin J, Szallasi Z, Bates PA, Swanton C, Gerlinger M.

Eur Urol. 2014 Nov;66(5):936-48. doi: 10.1016/j.eururo.2014.06.053. Epub 2014 Jul 19.

12.

Prognostic impact of intratumoral C-reactive protein expression in patients with clear cell renal cell carcinoma.

Can C, Acikalin MF, Ozen A, Dundar E.

Urol Int. 2014;92(3):270-5. doi: 10.1159/000353401. Epub 2013 Dec 19.

PMID:
24356040
13.

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.

Eur Urol. 2011 Sep;60(3):448-54. doi: 10.1016/j.eururo.2011.05.028. Epub 2011 May 17.

PMID:
21612860
14.

Expression of endothelin 2 and localized clear cell renal cell carcinoma.

Bot BM, Eckel-Passow JE, LeGrand SN, Hilton T, Cheville JC, Igel T, Parker AS.

Hum Pathol. 2012 Jun;43(6):843-9. doi: 10.1016/j.humpath.2011.07.011. Epub 2011 Nov 1.

15.

Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.

Isbarn H, Patard JJ, Lughezzani G, Rioux-Leclercq N, Crépel M, Cindolo L, de la Taille A, Zini L, Villers A, Shariat SF, Bertini R, Karakiewicz PI.

Urology. 2010 Jun;75(6):1378-84. doi: 10.1016/j.urology.2009.07.1221. Epub 2009 Sep 25.

PMID:
19781745
16.

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T, Cheville JC, Frenkel E, Rakheja D, Brugarolas J, Parker A.

Cancer. 2014 Apr 1;120(7):1059-67. doi: 10.1002/cncr.28521. Epub 2013 Dec 30. Erratum in: Cancer. 2014 Jun 1;120(11):1752-3.

17.

Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.

Belsante M, Darwish O, Youssef R, Bagrodia A, Kapur P, Sagalowsky AI, Lotan Y, Margulis V.

Urol Oncol. 2014 Jan;32(1):30.e23-8. doi: 10.1016/j.urolonc.2012.11.002. Epub 2013 Feb 18.

PMID:
23428539
18.

Evaluation of Argonaute protein as a predictive marker for human clear cell renal cell carcinoma.

Li W, Liu M, Feng Y, Xu YF, Che JP, Wang GC, Zheng JH, Gao HJ.

Int J Clin Exp Pathol. 2013 May 15;6(6):1086-94. Print 2013.

19.

Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma.

Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE.

Eur Urol. 2011 Jun;59(6):923-8. doi: 10.1016/j.eururo.2011.01.034. Epub 2011 Jan 28.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk